STIM logo

Neuronetics (STIM) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

28 June 2018

Indexes:

Not included

Description:

Neuronetics is a medical technology company that focuses on developing non-invasive treatments for mental health conditions. Their main product, the NeuroStar system, uses transcranial magnetic stimulation (TMS) to help patients with depression. The company aims to improve mental health care through innovative therapies.

Events Calendar

Earnings

Next earnings date:

Mar 05, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 05, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

14 Aug '24 JMP Securities
Market Outperform
13 Aug '24 Canaccord Genuity
Buy
12 Aug '24 William Blair
Market Perform
14 May '24 William Blair
Outperform
06 Mar '24 Piper Sandler
Overweight
10 May '23 JMP Securities
Market Outperform
08 Mar '23 JMP Securities
Market Outperform
08 Mar '23 Canaccord Genuity
Buy
14 Oct '21 JMP Securities
Market Outperform
13 Oct '21 BTIG
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
STIM
globenewswire.com20 November 2024

MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.

Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript
STIM
seekingalpha.com12 November 2024

Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity James Beers - William Blair Danny Stauder - JMP Operator Good day and thank you for standing by. Welcome to the Neuronetics Third Quarter 2024 Financial and Operating Results Conference Call.

Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
STIM
globenewswire.com12 November 2024

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024.

NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression
STIM
globenewswire.com14 October 2024

Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy

Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings
STIM
prnewswire.com04 October 2024

MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Plan of Arrangement"), pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Neuronetics will acquire all of the issued and outstanding common shares of Greenbrook ("Greenbrook Shares") in an all-stock transaction (the "Arrangement").

Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents
STIM
globenewswire.com25 September 2024

Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies

STIM Stock Likely to Gain From Updated TMS Coverage
STIM Stock Likely to Gain From Updated TMS Coverage
STIM Stock Likely to Gain From Updated TMS Coverage
STIM
zacks.com23 September 2024

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.

Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults
STIM
globenewswire.com19 September 2024

BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression

NeuroStar® Releases Software Upgrades to Elevate Patient Care
NeuroStar® Releases Software Upgrades to Elevate Patient Care
NeuroStar® Releases Software Upgrades to Elevate Patient Care
STIM
globenewswire.com16 September 2024

Upgrades improve communication, streamline data management, and strengthen security Upgrades improve communication, streamline data management, and strengthen security

NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories
STIM
globenewswire.com03 September 2024

NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives

FAQ

  • What is the primary business of Neuronetics?
  • What is the ticker symbol for Neuronetics?
  • Does Neuronetics pay dividends?
  • What sector is Neuronetics in?
  • What industry is Neuronetics in?
  • What country is Neuronetics based in?
  • When did Neuronetics go public?
  • Is Neuronetics in the S&P 500?
  • Is Neuronetics in the NASDAQ 100?
  • Is Neuronetics in the Dow Jones?
  • When was Neuronetics's last earnings report?
  • When does Neuronetics report earnings?
  • Should I buy Neuronetics stock now?

What is the primary business of Neuronetics?

Neuronetics is a medical technology company that focuses on developing non-invasive treatments for mental health conditions. Their main product, the NeuroStar system, uses transcranial magnetic stimulation (TMS) to help patients with depression. The company aims to improve mental health care through innovative therapies.

What is the ticker symbol for Neuronetics?

The ticker symbol for Neuronetics is NASDAQ:STIM

Does Neuronetics pay dividends?

No, Neuronetics does not pay dividends

What sector is Neuronetics in?

Neuronetics is in the Healthcare sector

What industry is Neuronetics in?

Neuronetics is in the Diagnostics & Research industry

What country is Neuronetics based in?

Neuronetics is headquartered in United States

When did Neuronetics go public?

Neuronetics's initial public offering (IPO) was on 28 June 2018

Is Neuronetics in the S&P 500?

No, Neuronetics is not included in the S&P 500 index

Is Neuronetics in the NASDAQ 100?

No, Neuronetics is not included in the NASDAQ 100 index

Is Neuronetics in the Dow Jones?

No, Neuronetics is not included in the Dow Jones index

When was Neuronetics's last earnings report?

Neuronetics's most recent earnings report was on 12 November 2024

When does Neuronetics report earnings?

The next expected earnings date for Neuronetics is 5 March 2025

Should I buy Neuronetics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions